Exciting Advances Are Coming for First-line CML Treatment
Kendra Sweet, M.D., discussed the various factors that must be taken into account when prescribing first-line therapies to patients with CML, the novel studies that are paving the way for improved outcomes in patients, and the increasing likelihood for TKI discontinuation on the horizon.
PUBLISHED: AUGUST 10, 2017
Promising treatment options are in the pipeline for patients with newly diagnosed chronic myeloid leukemia (CML), as groundbreaking trials are highlighting the potential of tyrosine kinase inhibitors (TKIs), such as Gleevec (imatinib), Sprycel (dasatinib) and Tasigna (nilotinib), explains Kendra Sweet, M.D.
Kendra Sweet, MD
Kendra Sweet, MD
The common practice has been to keep a patient on TKI therapy indefinitely, but according to Sweet, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, TKI discontinuation has been achieved and continues to be studied. In order to increase the potential for treatment discontinuation, a new combination therapy approach might need to be taken — something that Sweet says is currently being explored.
Once therapy is administered, it becomes necessary to monitor the patient on a continual basis to ensure long-term favorable outcomes. “Now that discontinuation is a real possibility for patients, [continual] monitoring becomes even more important because we want to maximize the chance that someone can actually get to that point and have that opportunity,” Sweet said in an interview with CURE.
Sweet discussed the various factors that must be taken into account when prescribing first-line therapies to patients with CML, the novel studies that are paving the way for improved outcomes in patients, and the increasing likelihood for TKI discontinuation on the horizon.
Can you give an overview of some of the main points in CML advances?One of the main points I brought up in my presentation was selection of firstline therapy for a newly diagnosed patient with CML. What are the factors that need to be considered when making the decision on how to appropriately treat someone in the upfront setting? We’re looking at things like risks scores, comorbidities and long-term goals, and then analyzing the data from all frontline studies to make a decision about how to best treat those patients.
Another key point was the need for frequent monitoring in CML— not just starting someone on therapy and hoping for the best. Monitoring according to the guidelines is necessary because there are certain mile stones that need to happen or be achieved in order to ensure long-term outcomes are favorable for these patients.
Finally, the new term, “TKI discontinuation,” suggests that there is a subset of patients who are likely to do very well when they have achieved a deep molecular response and we stop therapy.
What pivotal studies have led to the basis for what you use for frontline treatment?The three studies, which I showed today, were the IRIS trial, the DASISION trial and the ENESTnd trial. IRIS was a phase 3 study of Gleevec versus the prior standard of care, which was interferon and cytarabine. We now have long-term data from that study, that was published a couple of months ago with 10-year follow-up, which shows remarkable improvements in long-term survival in chronic-case patients with CML compared with the pre-Gleevec era looking at toxicities and things along those lines.
Talk about this article with other patients, caregivers, and advocates in the Myelodysplastic syndrome CURE discussion group.
Sometimes we can be regarded as being obsessed with cancer, but every single cancer survivor is more than that, and hold important roles in our lives to play.
In an interview with CURE Mesa, director, UT Health San Antonio Cancer Center, shed light on these recent updates in PV and ET, and discussed the proper therapeutic management of these diseases.
For the past four decades, there have been few advances in the treatment field of acute myeloid leukemia (AML). However, in the year 2017, there have been four new drugs approved by the FDA to treat the disease, with even more promising agents in the pipeline.
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Rami S. Komrokji, M.D., clinical director of Hematologic Malignancies at Moffitt Cancer Center, discusses an unmet need in the treatment of myelodysplastic syndrome (MDS).
Andrew Schorr, founder of Patient Power and Patient Empowerment and 2016 MPN Hero, discusses how his background in journalism led him to patient advocacy.